Coronavirus Infections: Clinical Trials

265 trials for Coronavirus Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

121 completed, 83 unknown, 27 terminated, 15 withdrawn. 265 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 4265Completed 121, Unknown 83, Terminated 27, Withdrawn 15, Recruiting 9, Active not recruiting 6, Suspended 3, Not yet recruiting 1

Follow Coronavirus Infections: new trials by email Literature Review of Coronavirus Infections trials Research Report on Coronavirus Infections

Trials (filtered) newest first · largest first

All 265 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations
mRNA-1273, mRNA-1283 - SARS-CoV-2
Phase 4RecruitingModernaTX, Inc.6002026-10-092026-11-04
Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19
Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M - COVID-19
Phase 4Active not recruitingSanofi6692026-10-012026-11-12
Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years
mCombriax® (mRNA-1083), Efluelda® (TIV-HD) and Spikevax® (mRNA-1273) - COVID-19, Influenza
Phase 4Not yet recruitingTor Biering-Sørensen4100002026-09-012026-08-27
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
BNT162b2 Vaccine, Tdap Vaccine - COVID-19 Vaccines
Phase 4RecruitingBioNTech SE2002026-07-232026-08-07
Steroid Treatment for Severe Acute Respiratory Infection (STAR) Trial
Corticosteroid - Hypoxemia, Severe Acute Respiratory Syndrome
Phase 4WithdrawnNational Institute of Allergy and Infectious Diseases (NIAID)2026-03-012026-11-17
Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19
mRNA-1273 (Moderna COVID-19 vaccine) - COVID-19
Phase 4CompletedTor Biering-Sørensen410602025-12-112026-10-06
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
mRNA-1273, mRNA-1283, Placebo - SARS-CoV-2
Phase 4Active not recruitingModernaTX, Inc.300002025-11-262026-09-28
Efficacy and Safety of NVX-CoV2705
NVX-CoV2705, Placebo - COVID-19, Sars-CoV-2 Infection
Phase 4TerminatedNovavax65002025-11-202026-10-23
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
Pfizer-BioNTech mRNA COVID-19 vaccine, Novavax recombinant protein vaccine - COVID -19, COVID - 19
Phase 4RecruitingHenry M. Jackson Foundation for the Advancement of Military Medicine542025-11-122026-11-02
Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious Pathogens
Ruconest - Post SARS-CoV2 (COVID-19), Post-Viral Fatigue Syndrome
Phase 4RecruitingIMMUNOe Research Centers302025-11-052026-11-12
COVID-19 Reactogenicity
Nuvaxovid (NVX-CoV2705), mNEXSPIKE mRNA-1283 - COVID-19
Phase 4Active not recruitingMarcel Curlin10002025-10-012026-03-04
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
mRNA-1283.251 Variant-containing Formulation - COVID-19
Phase 4CompletedModernaTX, Inc.8322025-07-212026-07-07
Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial
Nirmatrelvir/ritonavir, Remdesivir - SARS CoV-2 Post-Acute Sequelae
Phase 4RecruitingMount Sinai Hospital, Canada1182025-01-032025-01-24
An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.
Remdesivir - SARS-CoV-2 Infection, COVID-19
Phase 4CompletedUniversity of Derby732024-10-082026-02-20
Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses
BioNTech - Pfizer COVID-19 vaccine, 1mL saline solution, rVSV∆G-ZEBOV-GP - Ebola Virus Disease, COVID-19
Phase 4UnknownUniversity of Birmingham722024-10-012024-09-19
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine - COVID-19, Vaccine-Preventable Diseases
Phase 4CompletedNovavax6602024-09-192026-06-02
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
mRNA-1273 Variant-containing Formulation - SARS-CoV-2
Phase 4RecruitingModernaTX, Inc.11442024-09-092026-03-27
Anti-viral Action Against Type 1 Diabetes Autoimmunity
Comirnaty Injectable Product, Sodium Chloride 0.9% Inj - Diabetes Mellitus, Type 1
Phase 4RecruitingTechnical University of Munich22522024-05-082025-09-23
Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.
Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine - COVID-19, Long Haul
Phase 4RecruitingWell- Konnect Healthcare Services and Research Firm1002024-03-012024-11-27
Tetrandrine Tablets Used in Hospitalized Adults With COVID-19
Tetrandrine - COVID-19
Phase 4WithdrawnPeking University Third Hospital2023-12-312024-10-01

Showing 20 of 265. Sign in to see all of them.

Narrower conditions

COVID-19 (243)  ·  Severe Acute Respiratory Syndrome (10)  ·  Post-Acute COVID-19 Syndrome (9)  ·  Influenza, Human (8)  ·  Virus Diseases (8)  ·  Pneumonia (7)  ·  Respiratory Tract Infections (6)  ·  Infections (5)  ·  Pneumonia, Viral (5)  ·  Respiratory Distress Syndrome (5)  ·  Anosmia (4)  ·  HIV Infections (4)  ·  Pulmonary Disease, Chronic Obstructive (4)  ·  Bronchitis, Chronic (3)

Broader conditions

Coronaviridae Infections (263)  ·  Nidovirales Infections (263)  ·  RNA Virus Infections (263)  ·  Infections (260)  ·  Virus Diseases (257)  ·  Respiratory Tract Diseases (251)  ·  Lung Diseases (248)  ·  Respiratory Tract Infections (247)  ·  Pneumonia, Viral (243)  ·  Pneumonia (241)  ·  Pathological Conditions, Signs and Symptoms (43)  ·  Pathologic Processes (33)  ·  Disease Attributes (23)  ·  Chronic Disease (18)

Interventions

sinovac COVID-19 vaccine (20)  ·  Hydroxychloroquine (19)  ·  2019-nCoV Vaccine mRNA-1273 (15)  ·  BNT162 Vaccine (15)  ·  Standard of Care (11)  ·  Dexamethasone (10)  ·  Enoxaparin (8)  ·  Sodium Chloride (8)  ·  Ivermectin (7)  ·  Heparin (6)  ·  Lopinavir (6)  ·  Vaccines (6)  ·  remdesivir (6)  ·  Methylprednisolone (5)  ·  Vitamin D (5)

Sponsors

China National Biotec Group Company Limited (10)  ·  Sinovac Research and Development Co., Ltd. (9)  ·  Jiangsu Province Centers for Disease Control and Prevention (8)  ·  ClinAmygate (5)  ·  ModernaTX, Inc. (4)  ·  Shahid Beheshti University of Medical Sciences (4)  ·  Sinovac Life Sciences Co., Ltd. (4)  ·  Ain Shams University (3)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  Novartis Pharmaceuticals (3)  ·  Sinovac Biotech Co., Ltd (3)  ·  BioNTech SE (2)  ·  Brazilian Clinical Research Institute (2)  ·  Centre Hospitalier Universitaire de Saint Etienne (2)  ·  Clinical Urology and Epidemiology Working Group (2)

Countries

United States (65)  ·  China (51)  ·  Egypt (16)  ·  Spain (16)  ·  Brazil (15)  ·  Canada (8)  ·  Argentina (6)  ·  Belgium (6)  ·  Denmark (6)  ·  Netherlands (6)  ·  Pakistan (6)  ·  United Kingdom (6)  ·  Germany (5)  ·  India (5)  ·  Russia (5)

Top investigators

Jing-Xin Li, PhD (5)  ·  Hanqing He (4)  ·  Seyed Sina Naghibi Irvani, MD, MPH, MBA (4)  ·  Ruizhi Zhang (3)  ·  Aijaz Zeeshan Khan Chachar, MBBS,FCPS (2)  ·  Avni Thakore, MD (2)  ·  Dongjuan Zhang (2)  ·  Emad R Issak, MD (2)  ·  Fubing Wang (2)  ·  George Sakoulas, MD (2)  ·  Hongxing Pan, Master (2)  ·  Ilad Alavi Darazam, MD (2)  ·  Jens Lundgren, Professor (2)  ·  Jiang Wu, Master (2)

Results publications

PMID 35244208, PMID 34473343, PMID 33502773, PMID 37591523, PMID 36658045, PMID 37489818, PMID 11225528, PMID 11505791, PMID 16444180, PMID 16490989, PMID 17099299, PMID 20354090, PMID 23017003, PMID 23433693, PMID 27449641, PMID 28473851, PMID 29633177, PMID 30639191, PMID 31761015, PMID 32043986, PMID 32047895, PMID 32159775, PMID 32171076, PMID 32178593, PMID 32213556, PMID 32224164, PMID 32312790, PMID 32326426, PMID 32356926, PMID 32407672, PMID 32422305, PMID 32425001, PMID 32503662, PMID 32503663, PMID 32505069, PMID 32512291, PMID 32513231, PMID 32517353, PMID 32559419, PMID 32641154, PMID 32738928, PMID 32758441, PMID 32799933, PMID 32838353, PMID 32859459, PMID 32895056, PMID 33072620, PMID 33082342, PMID 33215159, PMID 33388170

NIH funding

1OT2HL156812-01 (1), 2025 (1), R01MD016872 (1)